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TIGAR [TP53 (tumour protein 53)-induced glycolysis and apoptosis regulator] is 
an important survival factor for cancer cells. The enzymatic activity supported 
by sequence analysis led Bensaad et al. to propose a fructose 2,6-
bisphosphatase function for TIGAR. TIGAR has thus received much attention 
within the biochemistry and cancer research communities given the key role of 
its substrate F26BP (fructose 2,6-bisphosphate), both as a positive allosteric 
effector of PFK1 (6-phosphofructo-1-kinase) and a negative allosteric effector of 
fructose-1,6-bisphosphatase, two master regulators of glycolysis and 
gluconeogenesis respectively. Thus p53-induced TIGAR confers cancer 
resistance against oxidative stress, since decreased F26BP shifts glycolysis to 
the PPP (pentose phosphate pathway), a metabolic route that, by regenerating 
NADPH(H+ ), a glutathione reductase cofactor, maintains the antioxidant 
glutathione in a reduced status. Furthermore, by restraining ROS (reactive 
oxygen species) levels, TIGAR can induce autophagy, hence moderating the 
apoptotic response. Besides TIGAR, cellular levels of F26BP are controlled by 
PFKFB1 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1)–PFKFB4, a 
family of bifunctional enzyme isoforms that differ in kinetic properties. Most 
PFKFB isoforms are regulated in order to equilibrate their 
kinase/bisphosphatase ratio to determine a particular level of F26BP. 
Accordingly, the extent whereby TIGAR can affect cellular F26BP concentration 
relies both on its own activity and on the specific PFKFB isoform that 
predominates in a given cell type or tissue. For instance, PFKFB3 is the isoform 
that has the highest (∼700:1) kinase/bisphosphatase ratio; accordingly, 
regulating PFKFB3 protein levels determines its kinase activity. However, in a 
previous study aimed to decipher the crystal structure of TIGAR, it was found 
that the catalytic efficiency of TIGAR as a fructose-2,6-bisphosphatase is 
several orders of magnitude lower than that of PFKFBs, thus questioning an 
efficient competition between TIGAR and PFKFBs at controlling F26BP levels. 
In this issue of the Biochemical Journal, Gerin et al. clarify the substrate 
preferences for TIGAR. As a first attempt, Gerin et al. screened several 
intracellular phosphate carboxylic acid esters as putative recombinant TIGAR 
substrates in vitro. They found 23BPG (2,3-bisphosphoglycerate) to be the best 
substrate, which TIGAR converted into 3-phosphoglycerate (Figure 1); in 
addition, although to a lesser catalytic efficiency, TIGAR also dephosphorylated 
2-phosphoglycerate, phosphoglycolate and phosphoenolpyruvate. Moreover, 
TIGAR was indeed able to dephosphorylate F26BP, but mostly (∼95%) to 
fructose 2-phosphate, in contrast with the bisphosphatase action of PFKFBs 
that exclusively form fructose 6-phosphate (Figure 1); however, the catalytic 
efficiency of TIGAR at dephosphorylating F26BP was approximately 400-fold 
lower than that observed for 23BPG. To assess the physiological relevance of 
these results and, in view that the high 23BPG concentration in erythrocytes 
masks the actual 23BPG concentration in blood-contaminated tissues in vivo, 
Gerin et al. examined 23BPG and F26BP levels in cultured cancer cells upon 
modulation of TIGAR.  
Thus TIGAR was first depleted in cells, which resulted in significant increases in 
23BPG without (or modestly) affecting F26BP. However, this lack of effect on 
F26BP could be ascribed to either any residual TIGAR protein left in the 
depleted cells, or to the fact that cancer cells may express other PFKFB 
isoform(s) that could dominate over TIGAR fructose-2,6-bisphosphatase 
activity. Accordingly, the authors knocked out TIGAR in mouse embryonic stem 
cells that express high levels of TIGAR; in TIGAR-knockout cells, 23BPG levels 
increased by 5-fold when compared with wild-typecells, whereas levels of 
F26BP increased by 3.5-fold. These results strongly suggest that 23BPG is a 
physiological substrate of TIGAR, and that the effect of TIGAR on cellular 
F26BP depends on the extent of the expression and/or activity of other fructose-
2,6-bisphosphatase(s) in a given physiological setting. The phosphatase activity 
on 23BPG is the result of the collective action of a family of phosphohistidine-
intermediate phosphatases, including, besides TIGAR, PGAMs 
(phosphoglycerate mutases) and BPGM (bisphosphoglycerate mutase). These 
enzymes differ in their mechanism of action and, importantly, in their 
dependence on phosphoglycolate for full activity. Thus Gerin et al. next aimed 
to decipher which type of 23BPG phosphatase TIGAR belongs to. According to 
its substrate preference, TIGAR resembled that of a previously identified 
phosphoglycolate-independent 23BPG phosphatase]. In addition, 
phosphoglycolate, far from activating, inhibited TIGAR activity; and, finally, the 
reported phosphoglycolateindependent 23BPG phosphatase activity was 
exclusively present in the fraction corresponding to TIGAR activity and 
immunoreactivity in mouse skeletal muscle protein extracts subjected to cation-
exchange chromatography. These results unambiguously demonstrate that 
TIGAR is the phosphoglycolateindependent 23BPG phosphatase (Figure 1). 
The results of Gerin et al. have important implications for several reasons. First, 
it appears that TIGAR is better suited to regulate 23BPG than F26BP, thus 
challenging the currently held notion that, biochemically, TIGAR is mainly a 
fructose-2,6-bisphosphatase. This is supported by: (i) the 400-fold TIGAR 
preference for 23BPG than for F26BP as substrate; and (ii) the higher increase 
in 23BPG than in F26BP concentrations in TIGAR-inhibited cells. Secondly, 
23BPG phosphatase activity would increase the glycolytic intermediates 
phosphoenolpyruvate and 2-phosphoglycerate, which stimulates, rather than 
inhibits, the terminal part of the glycolytic flux. This is difficult to reconcile with 
the reported inhibitory effect of TIGAR on glycolysis. However, it should be 
noted that the glucose assay specifically quantifies the flux from glucose to 
triose phosphates, making it possible that an activation of the terminal part of 
glycolysis could remain masked. In addition, the contribution of TIGAR at 
modulating F26BP depends on the specific PFKFB pattern of a given cell type. 
For instance, provided a predominant PFKFB isoform with low 
kinase/bisphosphatase ratio, TIGAR would have little impact on F26BP levels; 
however, in cells, such as neurons exclusively expressing the high 
kinase/bisphosphatase ratio isoform PFKFB3, TIGAR activity would have a 
stronger contribution to regulating F26BP levels.   
 
Finally, the results of Gerin et al. might explain a missing step of the glycolytic 
shunt (Figure 1), i.e. the pathway observed in cancer cells naturally 
overexpressing the form of PKM2 (pyruvate kinase M2) with low activity. 
Avoidance of the pyruvate kinase step allows a high glycolytic flux in the 
absence of a high ATP production, which is advantageous for cancer cells for 
biomass generation. This shunt requires the transfer of a phosphate group from 
phosphoenolpyruvate to PGAM1, and the phosphoenolpyruvate phosphatase 
activity of TIGAR may well accomplish this function; however, this still requires 
specific validation. Finally, given the well-known function of 23BPG as a 
negative allosteric effector of haemoglobin, it would be reasonable to speculate 
the possible role of TIGAR in regulating oxygen binding to haemoglobin. Gerin 
et al. discarded this possibility in viewof the unknown functional relevance of 
23BPG outside the erythrocytes. Indeed, haemoglobin in adult erythrocytes is 
fully saturated with 23BPG, which is at ∼5–10 mM in these cells. In addition, the 
lack of a nucleus (at least in mammals) hampers p53-induced TIGAR 
expression in erythrocytes. However, an increasing body of evidence now 
shows that haemoglobin is expressed in other cell types and tissues. For 
instance, both α- and β-subunits of haemoglobin are present in dopaminergic 
neurons, glia, macrophages, mesangial cells and glioblastoma and references 
cited therein). The functional relevance of haemoglobin occurrence in these 
cells is currently enigmatic; however, it has been suggested that it may play 
roles in ROS scavenging and mitochondrial biogenesis, indicating a biologically 
relevant function for haemoglobin in energy and redox homoeostasis control. 
Given that the 23BPG concentration in non-erythrocyte cells is ∼0.1 mM, the 
saturation curve of haemoglobin for 23BPG would be within the logarithmic 
phase. Thus one could hypothesize that, upon conditions of p53-mediated 
TIGAR induction, such as cancer, decreases in 23BPG levels would increase 
the affinity of haemoglobin for oxygen, probably causing local hypoxia. Whether 
this could account for the HIF1 (hypoxia-inducible factor 1)-mediated TIGAR 
mitochondrial re-localization remains to be elucidated; furthermore, such a 
putative local hypoxia might contribute to the Warburg effect. If so, through its 
ability to modulate 23BPG, TIGAR would represent a novel regulator of cell 
oxygen sensing in cancer cell metabolism and survival. 
 
According to the results of Gerin et al., TIGAR is a phosphoglycolate-independent 
23BPG phosphatase. As such, TIGAR-mediated modulation of 23BPG levels could 
have as-yet unrecognized biological functions. In a lower extent, TIGAR is also a 
phosphoenolpyruvate (PEP) phosphatase that Gerin et al. speculate could be 
responsible for the previously reported enzyme activity that phosphorylates, in a 
phosphoenolpyruvate-dependent manner, PGAM1 as part of the cancer-cell-specific 
glycolytic shunt. To a much lesser extent, TIGAR was found to dephosphorylate 
F26BP, a potent positive allosteric effector of PFK1, confirming previous results, 
although this activity mainly yielded fructose 2-phosphate (F2P), instead of fructose 6-
phosphate (F6P) like the bisphosphatase activity of PFKFBs. 13BPG, 1,3-
bisphosphoglycerate; BPGM, 1,3-bisphosphoglycerate mutase; ENO, enolase; 
F16BP, fructose 1,6-bisphosphate; 2-PG, 2-phosphoglycerate; 3-PG, 3-
phosphoglycerate; PGK, phosphoglycerate kinase; PKM, pyruvate kinase M; PYR, 
pyvuvate. 
 
 
 
 
